SCHEDULE 13G/A: EcoR1 Capital Amends Stake in Atea Pharmaceuticals, Disclosing 4.0% Beneficial Ownership

EcoR1 Capital, LLC and affiliated entities have filed an amended Schedule 13G, disclosing their beneficial ownership of 4.0% of Atea Pharmaceuticals, Inc.'s common stock as of December 31, 2024.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have filed an Amendment No. 4 to Schedule 13G regarding their beneficial ownership in Atea Pharmaceuticals, Inc.
• As of December 31, 2024, EcoR1 Capital, LLC and Oleg Nodelman each beneficially own 3,341,653 shares of Atea Pharmaceuticals, Inc. Common Stock, representing 4.0% of the class.
• EcoR1 Capital Fund Qualified, L.P. beneficially owns 3,156,745 shares, representing 3.7% of the class.
• The percentages are calculated based on 84,463,059 shares of Common Stock outstanding on November 4, 2024, as reported in Atea Pharmaceuticals, Inc.'s Form 10-Q for the quarter ended September 30, 2024.
• All reported shares are held with shared voting power and shared dispositive power by the respective reporting persons.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a routine disclosure of beneficial ownership and typically does not convey positive or negative sentiment regarding the issuer's performance or outlook. This amendment indicates a continued, non-controlling stake.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, confirming a non-activist stake.

Key Dates

Keywords

Atea Pharmaceuticals, EcoR1 Capital, Oleg Nodelman, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Biotechnology, Pharmaceuticals